Basic Information
RNALocate ID: | RLID:11000819 |
RNA Symbol: | hsa-miR-23a-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-23a |
RNA ID: | miRBase:MIMAT0000078 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20615901 |
Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
Method: | Microarray|RT-PCR |
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001321 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001322 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001323 | Mitochondrion | Myotube | 27396686 |
RLID:01001324 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001325 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001326 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001327 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001328 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000805 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
RLID:11000806 | Exosome | Pooled sera | 27278097 |
RLID:11000807 | Exosome | LAC cell line (A549) | 27492069 |
RLID:11000808 | Exosome | Saliva | 19627513 |
RLID:11000809 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11000810 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11000811 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000812 | Exosome | Renal cancer cells | 21670082 |
RLID:11000813 | Exosome | Ovarian follicular fluid | 22116803 |
RLID:11000814 | Exosome | Brain tissue | 23382797 |
RLID:11000815 | Exosome | Plasma | 23663360 |
RLID:11000816 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000817 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11000818 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000820 | Microvesicle | Plasma | 23077538 |
RLID:11000821 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000015 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Mast cells|Tongue tissue | |
RLID-D:11000277 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-23a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-31866 |
MNDR | hsa-miR-23a-3p | Colorectal adenoma | MNDR-E-MI-31867 |
MNDR | hsa-miR-23a-3p | Tongue squamous cell carcinoma | MNDR-E-MI-31868 |
MNDR | hsa-miR-23a-3p | Oral squamous cell carcinoma | MNDR-E-MI-31869 |
MNDR | hsa-miR-23a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-31870 |
MNDR | hsa-miR-23a-3p | Medulloblastoma | MNDR-E-MI-31871 |
MNDR | hsa-miR-23a-3p | B cell lymphoma of malt type | MNDR-E-MI-31872 |
MNDR | hsa-miR-23a-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-31873 |
MNDR | hsa-miR-23a-3p | Lymphoma | MNDR-E-MI-31874 |
MNDR | hsa-miR-23a-3p | Acute promyelocytic leukemia | MNDR-E-MI-31875 |
MNDR | hsa-miR-23a-3p | Anencephaly | MNDR-E-MI-31876 |
MNDR | hsa-miR-23a-3p | Niemann-pick disease type c | MNDR-E-MI-31877 |
MNDR | hsa-miR-23a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-31878 |
MNDR | hsa-miR-23a-3p | Prostate cancer | MNDR-E-MI-31879 |
MNDR | hsa-miR-23a-3p | Gastric cancer | MNDR-E-MI-31880 |
MNDR | hsa-miR-23a-3p | Leukodystrophy metachromatic | MNDR-E-MI-31881 |
MNDR | hsa-miR-23a-3p | Alzheimer disease | MNDR-E-MI-31882 |
MNDR | hsa-miR-23a-3p | Dysautonomia familial | MNDR-E-MI-31883 |
MNDR | hsa-miR-23a-3p | Myotonic dystrophy | MNDR-E-MI-31884 |
MNDR | hsa-miR-23a-3p | Head and neck cancer | MNDR-E-MI-31885 |
MNDR | hsa-miR-23a-3p | Vogt-koyanagi-harada disease | MNDR-E-MI-31886 |
MNDR | hsa-miR-23a-3p | Leukemia | MNDR-E-MI-31887 |
MNDR | hsa-miR-23a-3p | Huntington disease | MNDR-E-MI-31888 |
MNDR | hsa-miR-23a-3p | Chorea | MNDR-E-MI-31889 |
MNDR | hsa-miR-23a-3p | Cardiovascular disease | MNDR-E-MI-31890 |
MNDR | hsa-miR-23a-3p | Carotid stenosis | MNDR-E-MI-31891 |
MNDR | hsa-miR-23a-3p | Moyamoya disease | MNDR-E-MI-31892 |
MNDR | hsa-miR-23a-3p | Lung cancer | MNDR-E-MI-31893 |
MNDR | hsa-miR-23a-3p | Down syndrome | MNDR-E-MI-31894 |
MNDR | hsa-miR-23a-3p | Fragile x syndrome | MNDR-E-MI-31895 |
MNDR | hsa-miR-23a-3p | Parkinson disease | MNDR-E-MI-31896 |
MNDR | hsa-miR-23a-3p | Niemann-pick disease | MNDR-E-MI-31897 |
MNDR | hsa-miR-23a-3p | Colonic adenomas | MNDR-E-MI-31898 |
MNDR | hsa-miR-23a-3p | Breast cancer | MNDR-E-MI-31899 |
MNDR | hsa-miR-23a-3p | Pancreatic cancer | MNDR-E-MI-31900 |
MNDR | hsa-miR-23a-3p | Melanoma | MNDR-E-MI-31901 |
MNDR | hsa-miR-23a-3p | Lesch-nyhan syndrome | MNDR-E-MI-31902 |
MNDR | hsa-miR-23a-3p | Nephroblastoma | MNDR-E-MI-31903 |
MNDR | hsa-miR-23a-3p | Colon cancer | MNDR-E-MI-31904 |
MNDR | hsa-miR-23a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-31905 |
MNDR | hsa-miR-23a-3p | Familial ovarian cancer | MNDR-E-MI-31906 |
MNDR | hsa-miR-23a-3p | Prostate adenocarcinoma | MNDR-E-MI-31907 |
MNDR | hsa-miR-23a-3p | Carcinoma ductal breast | MNDR-E-MI-31908 |
MNDR | hsa-miR-23a-3p | Glioblastoma | MNDR-E-MI-31909 |
MNDR | hsa-miR-23a-3p | Astrocytoma | MNDR-E-MI-31910 |
MNDR | hsa-miR-23a-3p | Glioma | MNDR-E-MI-31911 |
MNDR | hsa-miR-23a-3p | Chordoma | MNDR-E-MI-31912 |
MNDR | hsa-miR-23a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-31913 |
MNDR | hsa-miR-23a-3p | Osteosarcoma | MNDR-E-MI-31914 |
MNDR | hsa-miR-23a-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-31915 |
MNDR | hsa-miR-23a-3p | Meningioma | MNDR-E-MI-31916 |
MNDR | hsa-miR-23a-3p | Liver cancer | MNDR-E-MI-31917 |
MNDR | hsa-miR-23a-3p | Uterine cancer | MNDR-E-MI-31918 |
MNDR | hsa-miR-23a-3p | Cervical adenocarcinoma | MNDR-E-MI-31919 |
MNDR | hsa-miR-23a-3p | Gastric adenocarcinoma | MNDR-E-MI-31920 |
MNDR | hsa-miR-23a-3p | Lung squamous cell carcinoma | MNDR-E-MI-31921 |
MNDR | hsa-miR-23a-3p | Non-small cell lung cancer | MNDR-E-MI-31922 |
MNDR | hsa-miR-23a-3p | Lung adenocarcinoma | MNDR-E-MI-31923 |
MNDR | hsa-miR-23a-3p | Thyroid carcinoma | MNDR-E-MI-31924 |
MNDR | hsa-miR-23a-3p | Ovarian carcinoma | MNDR-E-MI-31925 |
MNDR | hsa-miR-23a-3p | Pancreatic adenocarcinoma | MNDR-E-MI-31926 |
MNDR | hsa-miR-23a-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-31927 |
MNDR | hsa-miR-23a-3p | Carcinoma renal cell | MNDR-E-MI-31928 |
MNDR | hsa-miR-23a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-31929 |
MNDR | hsa-miR-23a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-31930 |
MNDR | hsa-miR-23a-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-31931 |
MNDR | hsa-miR-23a-3p | Cholangiocarcinoma | MNDR-E-MI-31932 |
MNDR | hsa-miR-23a-3p | Esophageal cancer | MNDR-E-MI-31933 |
MNDR | hsa-miR-23a-3p | Lung small cell carcinoma | MNDR-E-MI-31934 |
MNDR | hsa-miR-23a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-31935 |
MNDR | hsa-miR-23a-3p | T acute lymphoblastic leukemia | MNDR-E-MI-31936 |
MNDR | hsa-miR-23a-3p | Acute t cell leukemia | MNDR-E-MI-31937 |
MNDR | hsa-miR-23a-3p | Heart failure | MNDR-E-MI-31938 |
MNDR | hsa-miR-23a-3p | Fibromyalgia | MNDR-E-MI-31939 |
MNDR | hsa-miR-23a-3p | Adenoma | MNDR-E-MI-31940 |
MNDR | hsa-miR-23a-3p | Breast invasive carcinoma | MNDR-E-MI-31941 |
MNDR | hsa-miR-23a-3p | Hepatocellular carcinoma | MNDR-E-MI-31942 |
MNDR | hsa-miR-23a-3p | Familiar ovarian carcinoma | MNDR-E-MI-31943 |
MNDR | hsa-miR-23a-3p | B-cell lymphoma | MNDR-E-MI-31944 |
MNDR | hsa-miR-23a-3p | Rheumatoid arthritis | MNDR-E-MI-31945 |
MNDR | hsa-miR-23a-3p | Barrett's adenocarcinoma | MNDR-E-MI-31946 |
MNDR | hsa-miR-23a-3p | Osteoarthritis | MNDR-E-MI-31947 |
MNDR | hsa-miR-23a-3p | Hodgkin lymphoma | MNDR-E-MI-31948 |
MNDR | hsa-miR-23a-3p | Ulcerative colitis | MNDR-E-MI-31949 |
MNDR | hsa-miR-23a-3p | Burkitt lymphoma | MNDR-E-MI-31950 |
MNDR | hsa-miR-23a-3p | Tonsil cancer | MNDR-E-MI-31951 |
MNDR | hsa-miR-23a-3p | Acute myelogenous leukemia | MNDR-E-MI-31952 |
MNDR | hsa-miR-23a-3p | Colorectal cancer | MNDR-E-MI-31953 |
MNDR | hsa-miR-23a-3p | Nasopharynx carcinoma | MNDR-E-MI-31954 |
MNDR | hsa-miR-23a-3p | Type 2 diabetes mellitus | MNDR-E-MI-31955 |
MNDR | hsa-miR-23a-3p | Acute lymphocytic leukemia | MNDR-E-MI-31956 |
MNDR | hsa-miR-23a-3p | Ependymoma | MNDR-E-MI-31957 |
MNDR | hsa-miR-23a-3p | Cardiomegaly | MNDR-E-MI-31958 |
MNDR | hsa-miR-23a-3p | Nasopharyngeal cancer | MNDR-E-MI-31959 |
MNDR | hsa-miR-23a-3p | Prostatic neoplasms | MNDR-E-MI-31960 |
MNDR | hsa-miR-23a-3p | Sleep deprivation | MNDR-E-MI-31961 |
MNDR | hsa-miR-23a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-31962 |
MNDR | hsa-miR-23a-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-31963 |
MNDR | hsa-miR-23a-3p | Venous thromboembolism | MNDR-E-MI-31964 |
MNDR | hsa-miR-23a-3p | Stroke lacunar | MNDR-E-MI-31965 |
MNDR | hsa-miR-23a-3p | Barrett's carcinogenesis | MNDR-E-MI-31966 |
MNDR | hsa-miR-23a-3p | Tubulovillous adenoma | MNDR-E-MI-31967 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | APAF1 | Homo sapiens | RR00088393 |
TOP